Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 504-512

  Mahan, Charles E ^a   Spyropoulos, Alex C ^b   Fisher, Maxine D ^c   Fields, Larry E ^d   Mills, Roger M ^d   Stephenson, Judith J ^c   Fu, An Chen ^c   Klaskala, Winslow ^d  

^a New Mexico Heart Institute   (United States)

^b Lenox Hill Hospital of the North Shore/Long Island Jewish Health System ^*  (United States)

^c HEALTHCORE INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

anticoagulants; antiplatelet; bleeding; drugs; thrombosis prophylaxis; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD DYSCRASIA; BRAIN ISCHEMIA; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; ICD-9; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPLATELET; BLEEDING; DRUGS; THROMBOSIS PROPHYLAXIS; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84884251991     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612470967     Document Type: Article

References (41)

1. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003 ; 290 (14). 1868-1874
2. Kearon C. Natural history of venous thromboembolism. Circulation. 2003 ; 107 (23 suppl 1). I22 - I30
3. Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis.. 2010 ; 29 (3). 326-339
4. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007 ; 64 (1). 69-76
5. Tapson VF, Decousus H, Pini M, et al. Improve investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest.. 2007 ; 132 (3). 936-945
6. Tapson VE. Prophylaxis strategies for patients with acute venous thromboembolism. Am J Manag Care. 2001 ; 7 (17 suppl). S524 - S531
7. McKean SC, Deitelzweig SB, Sasahara A, Michota F, Jacobson A. Assessing the risk of thromboembolism and identifying barriers to thromboprophylaxis in the hospitalized patient. J Hosp Med. 2009 ; 4 (8 suppl). S1 - S7
8. Cohen AT, Davidson BL, Gallus AS, et al. ARTEMIS investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Brit Med J.. 2006 ; 332 (7537). 325-329
9. Samama M, Cohen AT, Darmon J-Y, et al. Prophylaxis in medical patients with enoxaparin study group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med.. 1999 ; 341 (11). 793-800
10. Ferretti G, Bria E, Giannarelli D, et al. Major bleedings in the comparisons between low-molecular-weight heparin versus oral anticoagulant therapy for venous thromboembolism. Thromb Res. 2007 ; 119 (4). 525-529
11. Zidane M, Schram MT, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med. 2000 ; 160 (15). 2369-2373
12. Ellis MH, Hadari R, Tchuvero N, et al. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost. 2006 ; 12 (2). 199-204
13. Rothschild S, Conen D. Characteristics of bleeding complications in patients with anticoagulation treatment. Swiss Med Wkly. 2008 ; 138 (47-48). 719-724
14. Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999 ; 159 (5). 457-460
15. Decousus H, Tapson VF, Bergmann JF, et al. Improve investigators. Factors at admission associated with bleeding risk in medical patients: findings from the Improve investigators. Chest.. 2011 ; 139 (1). 69-79
16. Trujillo-Santos J, Herrera S, Page MA, et al. RIETE investigators. Predicting adverse outcomes in outpatients with acute deep vein thrombosis: findings from the RIETE Registry. J Vasc Surg.. 2006 ; 44 (4). 789-793
17. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost. 2008 ; 100 (6). 1076-1083
18. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease. Arch Intern Med. 2007 ; 167 (2). 117-124
19. Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin?. J Gen Intern Med. 2004 ; 19 (8). 879-886
20. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main co medications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005 ; 61 (5-6). 439-444
21. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. Br Med J. 2006 ; 333 (7571). 726
22. Ruíz-Giménez N, Suárez C, González R, et al. RIETE investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism: findings from the RIETE Registry. Thromb Haemost.. 2008 ; 100 (1). 26-31
23. Jiménez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest. 2007 ; 132 (1). 24-30
24. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012 ; 21 (suppl 1). 154-162
25. Vekeman F, LaMori JC, Laliberté F, et al. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. J Med Econ. 2012 ; 15 (4). 644-653
26. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005 ; 43 (5). 480-485
27. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost. 2008 ; 100 (6). 1076-1083
28. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Is J Med. 1999 ; 107 (5). 414-424
29. Raeford DS, Perez Guttmann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996 ; 7 (1). 101-104
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical co morbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiology. 1992 ; 45 (6). 613-619
31. Spyropoulos AC, Anderson FA, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 ; 140 (3). 706-714
32. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 ; 8 (11). 2450-2457
33. Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge. Thrombosis J. 2011 ; 9 (1). 15
34. Monreal M, Falgá C, Valdés M, Suárez, et al. Riete investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006 ; 4 (9). 1950-1956
35. Imberti D, Agnelli G, Ageno W, et al. Master investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the master registry. Haematologica. 2008 ; 93 (2). 273-278
36. Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost. 2007 ; 98 (3). 656-661
37. Hashash JG, Shamseddeen W, Skoury A, Aoun N, Barada K. Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes. J Clin Gastroenterol. 2009 ; 43 (1). 36-42
38. Barada K, Abdul-Baki H, El Hajj II, Hashash JG, Green PH. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. J Clin Gastroenterol. 2009 ; 43 (1). 5-12
39. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008 ; 371 (9610). 387-394
40. Amin AN, Varker H, Princic N, Lin J, Thompson S, Johnston S.. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012 ; 7 (3). 231-238
41. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th end: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 2 suppl: e195S - e226S